SYK Stock Price Today (July 2026) — Stryker Corporation Analysis & Key Metrics 2026-07-17
Stryker Corporation (SYK) is trading at $319.87, down 3.42% today (as of July 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $386.80 (20.9% upside).
- Volatility remains elevated (39.63% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.60% YoY) alongside significant competitive pressures.
SYK Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Stryker Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $132.97B
P/E Ratio
Forward P/E: 18.83
Revenue Growth
Year over Year
Analyst Target
+20.9% upside potential
Key Investor Questions About SYK
What investors need to know before buying
Based on current market data, SYK presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 48.65)
- Fundamentals say: Caution warranted (high leverage concerns)
SYK's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for SYK investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $15.23B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, SYK stock traded between $281.00 and $404.87—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 39.63% annualized volatility and β=0.60, the stock exhibits low sensitivity to market moves—making SYK suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Stryker (SYK) Stock Looks Cheap On Cash Flow But Fair On Earnings
Stryker stock has given investors a 28.3% total return over the past five years, yet its current price around US$319.87 sits at a point where the Discounted Cash Flow (DCF) intrinsic value estimate suggests meaningful upside, while market based multiples look closer to fair. Over five years, Stryker has returned 28.3%, which points to steady but not dramatic long term gains for shareholders. New products such as the Mako RPS handheld robotic system can support expectations for future cash...
Mako Handheld Robotic Knee System Launch Might Change The Case For Investing In Stryker (SYK)
On 16 July 2026, Stryker announced the U.S. commercial launch of Mako RPS, a handheld robotic system for total knee replacement that combines intraoperative planning with a robotically enabled saw and integrates with its Triathlon Total Knee System and Q Guidance platform. This move extends the Mako ecosystem beyond robotic-arm systems into handheld robotics, potentially broadening adoption by matching robotic precision with familiar surgical workflows. Next, we’ll explore how expanding the...
Stryker (SYK) Launches Mako RPS As Its Valuation Story Comes Into Focus
Stryker (SYK) has drawn fresh attention after announcing the U.S. commercial launch of Mako RPS, a handheld robotic system for total knee replacements that extends its established Mako orthopaedic robotics portfolio. See our latest analysis for Stryker. The U.S. launch of Mako RPS comes as Stryker’s share price sits at US$319.87 after a recent pullback, with a 30 day share price return of 6.22% but a 1 year total shareholder return that declined 17.02%. This suggests enthusiasm around its...
Stryker Launches Mako RPS to Expand Robotic Knee Surgery Portfolio
SYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.
J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.
Why Abbott Stock Is Reimagining Its Future
Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.
J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others
Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.
The Open Questions On ISRG Stock
Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.
Why This Group Of Medical Giants, Including Intuitive Surgical, Just Took A Tumble
Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.
The Paid-To-Hold Play On ISRG Stock: A 12% Income
Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today's.
Frequently Asked Questions
Common investor questions about Stryker Corporation
Stryker Corporation (SYK) is currently trading at $319.87. The RSI (14-day) is at 48.7, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $386.80 implies 20.9% upside from current levels. Volatility is moderate at 39.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Stryker Corporation (SYK): The trailing P/E ratio is 37.06, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 18.83, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.50, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 5.34. Price-to-Sales is 4.85. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering SYK, the consensus price target is $386.80. This represents a 20.9% upside from the current price of $319.87. The range spans from a low target of $315.00 to a high target of $465.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Stryker Corporation (SYK) pays a dividend with a current yield of approximately 1.10%. The annualized dividend rate is $3.44 per share. The payout ratio is 39.8%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-06-30T00:00:00.000Z.
Key risks for Stryker Corporation (SYK) investors include: 1. Moderate volatility (39.6% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Stryker Corporation's (SYK) current debt and financial health profile: Total debt stands at $15.23B. The debt-to-equity ratio is 66.30, which is moderate and generally manageable for most companies. The current ratio is 2.11, indicating strong short-term liquidity. The quick ratio is 1.03. The company holds $2.96B in cash and equivalents. Free cash flow is positive at $4.36B, providing a cushion for debt servicing and shareholder returns.